Hikma 2020 financial results disappoint

25 February 2021
hikma-big

London-listed Hikma Pharmaceuticals (LSE: HIK) today reports its preliminary audited results for the year ended December 31, 2020, that disappointed and saw the firm’s share fall 7.9% to 2,227 pence in early trading.

Hikma reported core operating profit of $566 million, which missed a consensus forecast for $574 million. Group sales for the year were $2,341 million, just a fraction above consensus forecasts fo $2,340 million.

Core Group revenue growth of 6%, reflected growth in all three businesses, said Hikma. Core operating profit was up 11%, driven by strong growth in profit of Generics, with sales of $744 million, and Injectables, at $977 million, Branded sales were $613 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics